These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28254531)

  • 21. Analysis of gene expression pattern reveals potential targets of dietary oleoylethanolamide in reducing body fat gain in C3H mice.
    Thabuis C; Destaillats F; Landrier JF; Tissot-Favre D; Martin JC
    J Nutr Biochem; 2010 Oct; 21(10):922-8. PubMed ID: 19954948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antidepressant-like effects of oleoylethanolamide in a mouse model of chronic unpredictable mild stress.
    Jin P; Yu HL; Tian-Lan ; Zhang F; Quan ZS
    Pharmacol Biochem Behav; 2015 Jun; 133():146-54. PubMed ID: 25864425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine.
    Fu J; Astarita G; Gaetani S; Kim J; Cravatt BF; Mackie K; Piomelli D
    J Biol Chem; 2007 Jan; 282(2):1518-28. PubMed ID: 17121838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The satiety factor oleoylethanolamide impacts hepatic lipid and glucose metabolism in goldfish.
    Gómez-Boronat M; Velasco C; Isorna E; De Pedro N; Delgado MJ; Soengas JL
    J Comp Physiol B; 2016 Dec; 186(8):1009-1021. PubMed ID: 27277972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
    Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
    Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat.
    Hansen HS
    Pharmacol Res; 2014 Aug; 86():18-25. PubMed ID: 24681513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological functions and metabolism of oleoylethanolamide.
    Thabuis C; Tissot-Favre D; Bezelgues JB; Martin JC; Cruz-Hernandez C; Dionisi F; Destaillats F
    Lipids; 2008 Oct; 43(10):887-94. PubMed ID: 18704536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of food intake by oleoylethanolamide.
    Lo Verme J; Gaetani S; Fu J; Oveisi F; Burton K; Piomelli D
    Cell Mol Life Sci; 2005 Mar; 62(6):708-16. PubMed ID: 15770421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.
    Overton HA; Babbs AJ; Doel SM; Fyfe MC; Gardner LS; Griffin G; Jackson HC; Procter MJ; Rasamison CM; Tang-Christensen M; Widdowson PS; Williams GM; Reynet C
    Cell Metab; 2006 Mar; 3(3):167-75. PubMed ID: 16517404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A fatty gut feeling.
    Piomelli D
    Trends Endocrinol Metab; 2013 Jul; 24(7):332-41. PubMed ID: 23567058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties.
    Astarita G; Di Giacomo B; Gaetani S; Oveisi F; Compton TR; Rivara S; Tarzia G; Mor M; Piomelli D
    J Pharmacol Exp Ther; 2006 Aug; 318(2):563-70. PubMed ID: 16702440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.
    Borrelli F; Izzo AA
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):33-49. PubMed ID: 19285259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the satiety factor oleoylethanolamide in alcoholism.
    Bilbao A; Serrano A; Cippitelli A; Pavón FJ; Giuffrida A; Suárez J; García-Marchena N; Baixeras E; Gómez de Heras R; Orio L; Alén F; Ciccocioppo R; Cravatt BF; Parsons LH; Piomelli D; Rodríguez de Fonseca F
    Addict Biol; 2016 Jul; 21(4):859-72. PubMed ID: 26037332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1.
    Wang X; Miyares RL; Ahern GP
    J Physiol; 2005 Apr; 564(Pt 2):541-7. PubMed ID: 15695242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge eating disorder.
    Romano A; Micioni Di Bonaventura MV; Gallelli CA; Koczwara JB; Smeets D; Giusepponi ME; De Ceglia M; Friuli M; Micioni Di Bonaventura E; Scuderi C; Vitalone A; Tramutola A; Altieri F; Lutz TA; Giudetti AM; Cassano T; Cifani C; Gaetani S
    Neuropsychopharmacology; 2020 Oct; 45(11):1931-1941. PubMed ID: 32353860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
    González-Aparicio R; Moratalla R
    Neurobiol Dis; 2014 Feb; 62():416-25. PubMed ID: 24140894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons.
    Galan-Rodriguez B; Suarez J; Gonzalez-Aparicio R; Bermudez-Silva FJ; Maldonado R; Robledo P; Rodriguez de Fonseca F; Fernandez-Espejo E
    Neuropharmacology; 2009 Mar; 56(3):653-64. PubMed ID: 19070629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oleoylethanolamide Delays the Dysfunction and Death of Purkinje Cells and Ameliorates Behavioral Defects in a Mouse Model of Cerebellar Neurodegeneration.
    Pérez-Martín E; Muñoz-Castañeda R; Moutin MJ; Ávila-Zarza CA; Muñoz-Castañeda JM; Del Pilar C; Alonso JR; Andrieux A; Díaz D; Weruaga E
    Neurotherapeutics; 2021 Jul; 18(3):1748-1767. PubMed ID: 33829414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the area postrema in the hypophagic effects of oleoylethanolamide.
    Romano A; Gallelli CA; Koczwara JB; Braegger FE; Vitalone A; Falchi M; Micioni Di Bonaventura MV; Cifani C; Cassano T; Lutz TA; Gaetani S
    Pharmacol Res; 2017 Aug; 122():20-34. PubMed ID: 28535974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minireview: Endocannabinoids and their receptors as targets for obesity therapy.
    de Kloet AD; Woods SC
    Endocrinology; 2009 Jun; 150(6):2531-6. PubMed ID: 19372200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.